Stocks › PCRX

Pacira BioSciences, Inc.

PCRX·Nasdaq·United States United States·USD
$36.48
+0.00 (+0.00%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
PCRX
Pacira BioSciences, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
PCRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of PCRX by members of U.S. Congress · 17 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$15,001 - $50,000
Jul 1, 2022 May 30, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$15,001 - $50,000
Aug 26, 2021 May 31, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$1,001 - $15,000
Aug 26, 2021 Jan 25, 2021 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$1,001 - $15,000
Jun 23, 2021 May 6, 2021 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$1,001 - $15,000
Jun 12, 2021 Apr 20, 2021 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$1,001 - $15,000
Mar 5, 2021 Nov 2, 2020 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$15,001 - $50,000
Mar 5, 2021 May 31, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$1,001 - $15,000
Mar 5, 2021 Aug 23, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$15,001 - $50,000
Mar 5, 2021 Sep 26, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$1,001 - $15,000
Mar 5, 2021 Jan 15, 2021 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ PCRXPacira BioSciences, Inc. · Stock Purchase
$15,001 - $50,000
Mar 5, 2021 May 30, 2019 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH PCRXPacira BioSciences, Inc. · Stock Purchase
$50,001 - $100,000
Jan 24, 2017 Jan 13, 2017 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH PCRXPacira BioSciences, Inc. · Stock Sale
$1,001 - $15,000
Dec 20, 2016 Dec 13, 2016 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH PCRXPacira BioSciences, Inc. · Stock Purchase
$15,001 - $50,000
Jan 27, 2016 Jan 11, 2016 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH PCRXPacira BioSciences, Inc. · Stock Sale
$15,001 - $50,000
Dec 21, 2015 Dec 9, 2015 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH PCRXPacira BioSciences, Inc. · Stock Purchase
$1,001 - $15,000
Aug 11, 2015 Jul 21, 2015 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH PCRXPacira BioSciences, Inc. · Stock Purchase
$15,001 - $50,000
May 5, 2015 Apr 17, 2015 Filing ↗

Whale Activity

Position changes in PCRX reported for 2026-09-30 by 278 institutional filers
Increased: 88New: 29Held: 45Decreased: 79Closed: 21No prior filing: 16
  • Increased88
  • New29
  • Held45
  • Decreased79
  • Closed21
  • No prior filing16
FilerSharesValueChange
BlackRock, Inc.6.9M$173.7Mincreased
Doma Perpetual Capital Management LLC2.8M$69.6Mheld
VANGUARD PORTFOLIO MANAGEMENT LLC2.4M$59.4Mdecreased
DIMENSIONAL FUND ADVISORS LP2.3M$56.9Mincreased
STATE STREET CORP2.1M$53.7Mincreased
D. E. Shaw & Co., Inc.1.9M$46.9Mdecreased
RENAISSANCE TECHNOLOGIES LLC1.7M$41.9Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC1.6M$40.7Mdecreased
GOLDMAN SACHS GROUP INC1.5M$37.1Mdecreased
MORGAN STANLEY1.3M$32.1Mincreased
AMERICAN CENTURY COMPANIES INC1.2M$30.4Mincreased
GEODE CAPITAL MANAGEMENT, LLC1.1M$27.3Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by PCRX insiders, by quarter · Form 4
-50.0K-25.0K025.0K50.0K2025 Q1: -8792025 Q12025 Q2: -20.0K2025 Q22025 Q3: -7,2662025 Q32025 Q4: -41.0K2025 Q42026 Q1: -22.3K2026 Q12026 Q2: -41.4K2026 Q22026 Q3: -3,0402026 Q32026 Q4: -6,0002026 Q4

Recent Insider Transactions

1,158 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
RIKER LAURENSenior Vice President, Finance Sale −6,000 $36.32 $218K Oct 8, 2026 Form 4 ↗
SLONIN JONATHANChief Medical Officer Sale −3,040 $23.23 $71K Aug 17, 2026 Form 4 ↗
RIKER LAURENSenior Vice President, Finance Sale −6,115 $23.50 $144K Jun 11, 2026 Form 4 ↗
Hirawat SamitDirector Grant / award +6,405 $0.00 $0 Jun 10, 2026 Form 4 ↗
CHRISTIE CHRISTOPHERDirector Grant / award +6,405 $0.00 $0 Jun 10, 2026 Form 4 ↗
Young AlethiaDirector Grant / award +6,405 $0.00 $0 Jun 10, 2026 Form 4 ↗
YANG MICHAEL J.Director Grant / award +6,405 $0.00 $0 Jun 10, 2026 Form 4 ↗
BIGAL MARCELODirector Grant / award +6,405 $0.00 $0 Jun 10, 2026 Form 4 ↗
Froimson MarkDirector Grant / award +6,405 $0.00 $0 Jun 10, 2026 Form 4 ↗
Brege LauraDirector Grant / award +6,405 $0.00 $0 Jun 10, 2026 Form 4 ↗
WILLIAMS KRISTENChief Administrative Officer Sale −10.3K $22.27 $228K Jun 4, 2026 Form 4 ↗
RIKER LAURENSenior Vice President, Finance Tax withholding −3,187 $22.32 $71K Jun 3, 2026 Form 4 ↗
SLONIN JONATHANChief Medical Officer Tax withholding −4,728 $22.32 $106K Jun 3, 2026 Form 4 ↗
WILLIAMS KRISTENChief Administrative Officer Tax withholding −8,528 $22.32 $190K Jun 3, 2026 Form 4 ↗
Cross ShawnChief Financial Officer Sale −12.9K $25.16 $326K Apr 23, 2026 Form 4 ↗
Cross ShawnChief Financial Officer Option exercise +12.9K $16.45 $213K Apr 23, 2026 Form 4 ↗
Cross ShawnChief Financial Officer Sale −1,500 $25.01 $38K Apr 22, 2026 Form 4 ↗
Cross ShawnChief Financial Officer Option exercise +1,500 $16.45 $25K Apr 22, 2026 Form 4 ↗
Cross ShawnChief Financial Officer Sale −2,845 $25.01 $71K Apr 21, 2026 Form 4 ↗
Cross ShawnChief Financial Officer Option exercise +2,845 $16.45 $47K Apr 21, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding PCRX · SEC Form N-PORT
FundSharesValue% of fundAs of
iShares Core S&P Small-Cap ETF
iShares Trust
2.4M$60.2M0.05%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.2M$30.4M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
1.0M$26.2M0.03%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
856.2K$21.7M0.01%Jun 30, 2026
Impax Small Cap Fund
IMPAX FUNDS SERIES TRUST I
750.0K$19.0M2.00%Jun 30, 2026
Avantis U.S. Small Cap Value ETF
American Century ETF Trust
681.2K$17.6M0.06%Aug 31, 2026
U.S. SMALL CAP VALUE PORTFOLIO
DFA INVESTMENT DIMENSIONS GROUP INC
570.2K$15.1M0.08%Jul 31, 2026
VANGUARD SMALL-CAP VALUE INDEX FUND
VANGUARD INDEX FUNDS
542.9K$13.8M0.02%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
453.8K$11.5M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
432.5K$11.4M0.03%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list PCRX's shares (CUSIP 695127100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Vanguard Capital ManagementSCHEDULE 13G/A · passive (13G) · 1.9M shares4.8%
    Oct 30, 2026 · ↗
  • DOMA2 LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
    Oct 13, 2026 · ↗
  • The John Templeton FoundationSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
    Oct 13, 2026 · ↗
  • Pedro EscuderoSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
    Oct 13, 2026 · ↗
  • DOMA Perpetual Partners GP LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
    Oct 13, 2026 · ↗
  • DOMA Perpetual LO Equity Master Fund LPSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
    Oct 13, 2026 · ↗
  • DOMA1 LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
    Oct 13, 2026 · ↗
  • Doma Perpetual Capital Management LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
    Oct 13, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 2.1M shares5.2%
    Aug 7, 2026 · ↗
  • Vanguard Portfolio ManagementSCHEDULE 13G · passive (13G) · 2.6M shares6.4%
    May 1, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Pacira BioSciences, Inc. as client

No lobbying filings found naming Pacira BioSciences, Inc. as the client.

Government Contracts

Federal awards to Pacira BioSciences, Inc. · USAspending

No federal contract awards found for Pacira BioSciences, Inc..

U.S. Patents

Recent USPTO applications naming Pacira BioSciences, Inc.

No USPTO patent applications found for Pacira BioSciences, Inc..

Annual Financials

From PCRX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$726.4M$701.0M$675.0M$666.8M$541.5M
Operating income$19.2M-$73.4M$87.7M$60.0M$89.9M
Net income$7.0M-$99.6M$42.0M$15.9M$42.0M
Diluted EPS$0.16-$2.15$0.89$0.34$0.92
Operating cash flow$152.0M$189.4M$154.6M$145.3M$125.7M
Cash and equivalents$158.5M$276.8M$153.3M$104.1M$585.6M
Total assets$1.26B$1.55B$1.57B$1.68B$2.08B
Total liabilities$571.8M$775.2M$704.3M$906.2M$1.34B
Shareholders' equity$693.1M$778.3M$870.1M$775.0M$730.4M

As Pacira BioSciences, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in PCRX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 1.01, 1.02, 2.01, 2.04, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01Material agreement · Termination of agreement · Acquisition or dispositionNov 17, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureNov 12, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureNov 5, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureOct 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureJun 30, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 8.01, 9.01Officer / director change · Shareholder vote · Other eventsJun 11, 2026
    EDGAR ↗

About Pacira BioSciences, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBRISBANE, CA
IncorporatedDE
Former namesPacira Pharmaceuticals, Inc., PACIRA INC, Blue Acquisition Corp